Dextromethorphan/quinidine, whose trade name Nuedexta, is a combination drug containing
dextromethorphan and the antiarrhythmic agent quinidine. Quinidine is included to inhibit
dextromeththorphan metabolism. For more information go to : https://www.nuedexta.com
This pilot-study (NCT01767129) examined the safety and efficacy of dextromethorphan plus
quinidine for treating L-dopa induced dyskinesia. People with Parkinson's Disease were
randomised to 45mg dextromethorphan and 10mg twice daily, alternated with a placebo.
The main assessment was dyskinesia severity. Dyskinesia
severity was a bit lower with dextromethorphan and quinidine
than with a placebo, and subsequently significantly lower.
Most of the patients rated their dyskinesia "much or very much
improved" when taking dextromethorphan and quinidine.
Dextromethorphan and quinidine did not worsen Parkinson's
Disease motor scores, was generally well tolerated, but was
associated with more frequent adverse effects. This study
provides preliminary evidence of clinical benefit with
dextromethorphan / quinidine for treating L-dopa induced
dyskinesia in Parkinson's Disease. Larger studies with a longer
treatment duration are needed to corroborate these findings.
Reference : Movement Disorders [2017] Mar 30 [Epub ahead of print] (S.H.Fox, L.V.
Metman, J.G.Nutt, M.Brodsky, S.A.Factor, A.E.Lang, L.E.Pope, N.Knowles, J.Siffert)
Complete abstract : http://www.ncbi.nlm.nih.gov/pubmed/28370447
http://www.viartis.net/parkinsons.disease/news/170409.pdf
mail@viartis.net
©2017 Viartis
http://www.viartis.net/parkinsons.disease/news/170409.pdf
No comments:
Post a Comment